TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03768154

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Supine + spontaneous effort
Description: without muscle paralysis in supine position

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Supine + paralysis
Description: administer muscle paralysis in supine position

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Prone + paralysis
Description: change the patient position from supine to prone with muscle paralysis

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Prone + spontaneous breathing
Description: cease the paralysis in supine position
Study: NCT01547442

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Artisan Aphakia Intraocular Lens
Description: Implantation of an intraocular lens
Study: NCT01570361

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Catheter Ablation
Description: Treat subjects with Paroxysmal Atrial Fibrillation (PAF)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Drug Treatment
Description: Drug therapy (either rate or rhythm control): Class I or class III, or AV nodal blocking agents such as beta blockers and calcium channel blockers in accordance with current atrial fibrillation management guidelines.
Study: NCT04274010

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: PillCamTM Crohn's capsule
Description: Capsule endoscopy for small and large bowel to assess Crohn's disease activity.

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Magnetic resonance enterography
Description: MRI scan of small bowel to assess small bowel Crohn's disease activity.

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Ileo-colonoscopy
Description: Endoscopic procedure to assess Crohn's disease activity in colon and terminal ileum.
Study: NCT06732479

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioural Skill Training Programme
Description: BST was administered in 3 sessions in a week on alternate days, each session lasting for an hour. Training was given in small groups consisting of 4-6 members. Parents were involved as co-therapists, and observed the training given by the researcher and practiced it at home with their children.~The training was carried out through the following steps:~1. Instruction- Involved teaching the location of private parts, difference between appropriate and inappropriate touch, safe and unsafe secrets, sexuality, self-protection skills (saying NO, move from situation, tell trusted person, report the person and situation.~2. Modelling- researcher, modelled, correct responses, and instructed to act in the unsafe situation using role play. Situations were presented using video.~3. Rehearsal-researcher presented situations using video and instructed to rehearse the skills until able to demonstrate the skill independently
Study: NCT02540148

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Nova Oculus™ Micro-current electrical stimulation
Description: Active treatment with transpalpebral micro-current electrical stimulation device, 3 sessions within 5 days of the 1st treatment. 1 session during weeks 2, 14 and 26.
Study: NCT01094158

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aramchol
Description: 100mg/d tablets packaged in bottles given orally once a day in the morning within 10 minutes after breakfast for a total period time of 3 months

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aramchol
Description: 300 mg/d tablets packaged in bottles given orally once a day in the morning within 10 minutes after breakfast for a total period time of 3 months

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: tablets packaged in bottles given orally once a day in the morning within approximately 10 minutes after breakfast
Study: NCT01639820

Intervention type: PROCEDURE
Group type: OTHER
Intervention: identification of sentinel nodes + full pelvic lymph-node dissection
Description: identification of sentinel nodes + full pelvic lymph-node dissection

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: only identification of sentinel nodes (without pelvic lymph-node dissection)
Description: only identification of sentinel nodes (without pelvic lymph-node dissection)
Study: NCT04144894

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Shear Wave Elastography
Description: Advanced ultrasound technique

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Shear Wave Elastography
Description: Advanced ultrasound technique
Study: NCT06684574

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Nordic walking program
Description: The intervention is a defined program of Nordic walking and strengthening exercises for 10 weeks in a regimen of two days per week (two 75-minute sessions per week). In these sessions, they did Nordic walking three 5-minute breaks, where strength and proprioception exercises of the lower extremities were performed.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Educational advise
Description: Patients in the control arm participated in a single session to advise them on the need for self-exercise.
Study: NCT02220036

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Magnesium Oxide
Description: Patients aged more than 18 years old with diabetic nephropathy having Fasting Blood Sugar more than 126 mg/dL and proteinuria 30-300 mg/dL (microalbuminuria) and Glomerular Filtration Rate more than 90 mL/min will be chosen. Patient group will receive magnesium supplement (250 milligram) and the other group will receive placebo which is similar to the magnesium tablets in color, odor and appearance both for 12 weeks. All subjects will complete 4 physical activity and 4 dietary records. Outcome measurements including metabolic, renal and inflammatory profiles will be measured at the beginning and end of the study as well as anthropometric measurements.
Study: NCT02069808

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Follistim
Description: Follicle stimulating hormone promotes recruitment of follicles for ovulation.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Follistim
Description: Follicle stimulating hormone promotes recruitment of follicles for ovulation.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ganirelix
Description: GnRH antagonist preventing a problematic risk of premature LH surge during ovulation induction therapy.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ganirelix
Description: GnRH antagonist preventing a problematic risk of premature LH surge during ovulation induction therapy.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Menotropins
Description: Combination of follicle stimulating hormone and Luteinizing hormone activity promotes recruitment of follicles for ovulation. Absence or presence of this medication is the difference being tested between the two arms of the study.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Leuprolide
Description: Promotes endogenous LH surge signaling oocyte maturation followed by ovulation. This controls timing for oocyte collection.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leuprolide
Description: Promotes endogenous LH surge signaling oocyte maturation followed by ovulation. This controls timing for oocyte collection.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Transvaginal ultrasound guided needle aspiration of oocytes

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Transvaginal ultrasound guided needle aspiration of oocytes
Study: NCT04237064

Intervention type: DIAGNOSTIC_TEST
Intervention: Photoacoustic imaging
Description: Photoacoustic imaging
Study: NCT04504214

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Upper limb repeated multi-site tendon vibrations
Description: Upper limb tendon vibration protocol will be added to the usual rehabilitation protocol performed during hospitalization

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Upper limb repeated multi-site tendon vibrations
Description: Upper limb tendon vibration protocol will be added to the usual rehabilitation protocol performed during hospitalization
Study: NCT02774330

Intervention type: OTHER
Intervention: Policy
Description: This local policy change (i.e., the Minneapolis Staple Foods Ordinance) establishes minimum stocking criteria for a wide array of healthy foods as a requirement of food store licensing. To our knowledge, it is the first and only policy of its kind in the U.S. This Staple Foods Ordinance requires stores to stock specific types of foods in minimum quantities and varieties, including fruits and vegetables, low-fat dairy, and whole grains. A full list of all requirements can be found online through the City of Minneapolis: http://www.minneapolismn.gov/health/living/eating/staple-foods.
Study: NCT04426721

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ozone
Description: 10 cc of oxygen-ozone

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hyaluronic Acid
Description: Sinovial forte 32 mg\\2ml
Study: NCT02540148

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Nova Oculus™ Micro-current electrical stimulation - Sham treatment
Description: Non-active treatment with transpalpebral micro-current electrical stimulation SHAM device, 3 sessions within 5 days of the 1st treatment. 1 session during weeks 2, 14 and 26.
Study: NCT02260375

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Mesenchymal Stromal Cells
Study: NCT03779191

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alectinib
Description: Alectinib dosed 600 mg twice a day (BID) with meals until disease progression, unacceptable toxicity, or other reasons specified in the protocol

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Bevacizumab 15 mg/kg intravenously every 3 weeks until disease progression, unacceptable toxicity, or other reasons specified in the protocol
Study: NCT03252288

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Reminders
Description: Text of phone-call based reminders to mobile phones

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Reminders
Description: Text of phone-call based reminders to mobile phones

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Conditional financial transfers
Description: Full amount paid if visit occurs within 1 week of the scheduled visit; partial amount is paid if visit occurs \>1 week but within 4 weeks of the scheduled visit
Study: NCT02066584

Intervention type: OTHER
Intervention: Sibling oocyte incubation

Intervention type: OTHER
Intervention: Sibling oocyte incubation

Intervention type: OTHER
Intervention: Sibling oocyte incubation

Intervention type: OTHER
Intervention: Sibling oocyte incubation
Study: NCT02089542

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: MB and fluorescent imaging
Description: Single arm study for the development of a protocol stipulating the optimum dose and time to peak near infra-red fluorescence from intraoperative injection of low dose Methylthioninium chloride
Study: NCT00850408

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Repetitive Transcranial Magnetic Stimulation
Description: For real rTMS,1200 pulses will be delivered at a frequency of 1Hz, with an intensity equal to the 115% of the motor threshold as established at baseline. For Sham rTMS, procedures will be identical to those used for real rTMS with the exception that a placebo coil will be used, which provides acoustic and sensory stimulation like the real coil but does not stimulate neural tissue. 20-minute Real and Sham stimulation sessions will be administered bi-weekly for a period of 4 weeks

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Repetitive Transcranial Magnetic Stimulation
Description: For real rTMS,1200 pulses will be delivered at a frequency of 1Hz, with an intensity equal to the 115% of the motor threshold as established at baseline. For Sham rTMS, procedures will be identical to those used for real rTMS with the exception that a placebo coil will be used, which provides acoustic and sensory stimulation like the real coil but does not stimulate neural tissue. 20-minute Real and Sham stimulation sessions will be administered bi-weekly for a period of 4 weeks
Study: NCT00440531

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Comparator: RECOMBIVAX HB™ Hepatitis B Vaccine (Recombinant)
Description: RECOMBIVAX HB™ (currently licensed product) given IM (Intramuscular) in 3 doses of 10 mcg (micrograms)/1.0 mL each over 6 months.
Study: NCT02382497

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: AN Active tDCS
Description: The tDCS active stimulations will be directed to PFC regions for six weeks delivered for three times a week.~tDCS will be delivered by a battery driven, constant current stimulator through a pair of saline-soaked sponge electrodes kept firm by elastic bands.~The anode will be placed on the left PFC, F3 position according to the 10-20 international EEG system for electrode placement, while the cathode will be placed on the right PFC, F4 position according to the 10-20 international EEG system for electrode placement.~Stimulation intensity will be set at 1 milliampere (mA), the duration of stimulation will be 20 min.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: AN Sham tDCS
Description: The same electrode placement will be used as in the stimulation conditions (left anodal/right cathodal), but the current will be applied for 30 s and will be ramped down without the participants awareness, and will be held three times a week for six weeks.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: BED Active tDCS
Description: The tDCS active stimulations will be directed to PFC regions for six weeks delivered for three times a week.~tDCS will be delivered by a battery driven, constant current stimulator through a pair of saline-soaked sponge electrodes kept firm by elastic bands.~For the OW/OB with diagnosis of BE, or food craving, the anode will be placed on the right PFC, F4 position according to the 10-20 international EEG system for electrode placement, while the cathode will be placed on the left PFC, F3 position according to the 10-20 international EEG system for electrode placement.~Stimulation intensity will be set at 1 milliampere (mA), the duration of stimulation will be 20 min.
Study: NCT00440531

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Comparator: Modified Process Hepatitis B Vaccine (Experimental)
Description: Modified Process Hepatitis B Vaccine (Experimental) given IM (Intramuscular) in 3 doses of 10 mcg (micrograms)/1.0 mL each over 6 months.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Comparator: ENGERIX-B™ (currently licensed product)
Description: ENGERIX-B™ given IM (Intramuscular) in 3 doses of 20 mcg (micrograms)/1.0 mL each over 6 months.
Study: NCT01746342

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Effective continuous positive airway pressure (CPAP)

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham continuous positive airway pressure (CPAP)
Study: NCT02382497

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: BED Sham tDCS
Description: The same electrode placement will be used as in the stimulation conditions (right anodal/left cathodal), but the current will be applied for 30 s and will be ramped down without the participants awareness, and will be held three times a week for six weeks.
Study: NCT04554810

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Medication Management Service
Description: Medication review was delivered to the Syrian refugees by accredited pharmacists at the baseline visit. This followed by identifying the treatment-related problems (TRP) by the clinical pharmacist, and correction of the approved TRPs by the corresponding physicians and finally convey these changes in medications to the patients. In addition, counselling and education were delivered to the refugees' patients in the base line visit.
Study: NCT00077142

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAC-101
Description: Once daily by mouth on days 1-14, repeat every 21 days for 2 courses.
Study: NCT04437251

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcranial direct current stimulation (tDCS)
Description: Transcranial direct current stimulation (tDCS) is an non-invasive, low-intensity direct current stimulation. The stimulation intensity is very low (0- 2 mA) to only produce tingling sensation on the scalp. From literature, there were no serious adverse effects reported after 20-minute stimulation. The main temporary side effect is skill irritation, itching sensation at the stimulation site during or after stimulation.
Study: NCT02972684

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Thrombo-elastometry POC testing
Description: Use of thrombo-elastometry point of care test and algorithm guided predetermined intervention during peri operative haemorrhage
Study: NCT01798810

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Supplemental Perioperative Oxygen
Description: Patients receiving perioperative oxygen will receive 80% FiO2 during surgery.
Study: NCT02148757

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Doppler Ultrasound
Study: NCT02055989

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Dose-escalated radiotherapy level 1

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Sequential dose-escalated radiotherapy level 2
Study: NCT04437251

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Transcranial direct current stimulation (tDCS)
Description: Transcranial direct current stimulation (tDCS) is an non-invasive, low-intensity direct current stimulation. The stimulation intensity is very low (0- 2 mA) to only produce tingling sensation on the scalp. From literature, there were no serious adverse effects reported after 20-minute stimulation. The main temporary side effect is skill irritation, itching sensation at the stimulation site during or after stimulation.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcranial direct current stimulation (tDCS)
Description: Transcranial direct current stimulation (tDCS) is an non-invasive, low-intensity direct current stimulation. The stimulation intensity is very low (0- 2 mA) to only produce tingling sensation on the scalp. From literature, there were no serious adverse effects reported after 20-minute stimulation. The main temporary side effect is skill irritation, itching sensation at the stimulation site during or after stimulation.
Study: NCT04616508

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: motor control assessment
Description: Basic science study of control of reaching movements
Study: NCT01394965

Intervention type: PROCEDURE
Group type: NO_INTERVENTION
Intervention: ECG electrodes
Description: Cardiac mapping of patients before and after ablation to develop future treatment/diagnostic options for cardiac patients.
Study: NCT01562782

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Fructose + Glucose Beverage
Description: Consumption of a sweet beverage (Fructose:Glucose 1:1, 3g/kg) over 1/2 hour. Blood sampling will occur before and after consumption of beverage.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Fructose + Glucose Beverage
Description: Consumption of a sweet beverage (Fructose:Glucose 1:1, 3g/kg) over 1/2 hour. Blood sampling will occur before and after consumption of beverage.
Study: NCT03149432

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Mirror Therapy
Description: by a mirror effect the patient sees his remaining arm at the place of the amputated arm that cause an illusion of presence of this arm to the brain and would have an effect of reducing phantom pain
Study: NCT02807896

Intervention type: OTHER
Description: This study is cohort.

Intervention type: OTHER
Description: This study is cohort.

Intervention type: OTHER
Description: This study is cohort.

Intervention type: OTHER
Description: This study is cohort.

Intervention type: OTHER
Description: This study is cohort.
Study: NCT02062268

Intervention type: BEHAVIORAL
Intervention: health education & law enforcement

Intervention type: BEHAVIORAL
Intervention: health education & law enforcement

Intervention type: BEHAVIORAL
Intervention: health education & law enforcement

Intervention type: BEHAVIORAL
Intervention: health education & law enforcement

Intervention type: BEHAVIORAL
Intervention: health education & law enforcement
Study: NCT02245932

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Resveratrol
Description: 4 weeks of 150 mg resveratrol (2 times 75mg/day)

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 4 weeks of placebo supplementation (two doses per day)
Study: NCT03151005

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin-GLP-1 Receptor Agonist
Description: metformin oral with exenatide/liraglutide subcutaneous injection.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin-Oral Contraceptive(OC)
Description: metformin with Diane 35 oral intake.
Study: NCT03339674

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Psychoeducational Group Intervention on Alcohol Drinking Related to Stress
Description: Manualized and standardized psychotherapeutic group intervention with three sessions of 60 min duration each which are to be delivered in a one-week period.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Cognitive Training
Description: Manualized and standardized psychotherapeutic group intervention with three sessions of 60 min duration each which are to be delivered in a one-week period.
Study: NCT00156065

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Haloperidol
Description: 2-8 mg BID

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Asenapine
Description: 5 or 10 mg BID

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Asenapine
Description: 5 or 10 mg BID
Study: NCT04473131

Intervention type: OTHER
Intervention: No intervention
Description: Only blood samples will be taken from participants for this study

Intervention type: OTHER
Intervention: No intervention
Description: Only blood samples will be taken from participants for this study

Intervention type: OTHER
Intervention: No intervention
Description: Only blood samples will be taken from participants for this study